Key result
Mild COVID-19 in T2D is linked to ~56% higher hepatic lipid content at 1 year.
Why the study?
The effect of COVID-19 on hepatic lipid content, fibrosis risk, and adiposity in persons with type 2 diabetes was not established.
Does mild COVID-19 infection increase hepatic lipid content in persons with type 2 diabetes?
Cohort (n=29)
Does mild COVID-19 infection increase hepatic lipid content in persons with type 2 diabetes?
Effect estimate: Relative increase 56% (95% CI 18%, 106%)
p-value: p=0.04
Mild COVID-19 infection in patients with type 2 diabetes is associated with a significant increase in hepatic lipid content one year after recovery.
Introduction The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes. Research design and methods Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58±12 years, body mass index 30.9±5.2 kg/m 2 ) were examined before (baseline) and 1 year (12±2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61±6 years, 30.0±4.6 kg/m 2 ). Results COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed. Conclusions History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection. Trial registration number NCT01055093 .
No takes yet. Share an insight, caveat, or question.
Kupriyanova et al. (2025) conducted a cohort in Type 2 diabetes with a history of mild COVID-19 (n=29). Mild COVID-19 infection vs. No COVID-19 infection was evaluated on Hepatic lipid (HL) content measured as proton density fat fraction (HL-PDFF) (Relative increase 56%, 95% CI 18%, 106%, p=0.04). Mild COVID-19 in persons with type 2 diabetes was associated with a 56% relative increase in hepatic lipid content at 1 year compared to those without COVID-19 (95% CI 18-106%; p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: